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Cells control their own death through a program
termed apoptosis, which is indispensable for devel-
opment and homeostasis in all metazoans. Lyso-
somal cysteine proteases are not normally thought
of as participating in apoptosis; however, recent
reports have shown that the cathepsin proteases
can be released from the lysosome during apoptosis,
where they can participate in cell death. We report
here the development of an activity-based probe
that, under optimized conditions, reports on cathep-
sin B activity only in apoptotic cells by reading out
the release of cathepsin B from the lysosomes. Bio-
chemical characterization of apoptosis in cells from
cathepsin B null mice shows delayed and suboptimal
activation of caspases. Our data further supports
a role for cathepsin B in the cytosol as a positive
regulator of a cell death feed-forward loop and
provides a chemical tool for future investigations.
INTRODUCTION
Apoptosis is a tightly regulated form of programmed cell death
that plays an essential role in the development and homeostasis
in all metazoans (Danial and Korsmeyer, 2004; Rathmell and
Thompson, 2002; Zheng et al., 1999). Deficiency in apoptosis
is a feature of cancer and autoimmune diseases, whereas
improper overactivation of this death program is linked to neuro-
degenerative disorders (Green and Evan, 2002; Hanahan and
Weinberg, 2000; Vaux and Flavell, 2000; Yuan and Yankner,
2000). Two major apoptotic pathways exist in cells, the intrinsic
pathway, which senses cellular stress, and the extrinsic path-
way, which is induced by extracellular signals such as Fas
binding to its cognate death receptor (Riedl and Shi, 2004).
Central to both pathways is the cascading activation of a family
of cysteine proteases know as the caspases, which are synthe-
sized as inactive zymogens. Upon activation by cross-autopro-
cessing through dimer- or oligomerization, initiator caspases
(caspase-8, -9, and -10) cleave and thereby activate the effector
caspases (caspase-3, -6, and -7), which then go on to deacti-Chemistry & Biology 16, 1001–101vate, and in some cases activate, numerous cellular targets by
proteolytic processing after key aspartate residues (Dix et al.,
2008; Mahrus et al., 2008).
Current methods for visualizing these cascades depend
heavily on antibodies to detect full-length and/or cleaved, there-
fore presumably activated, caspases. However, there is evi-
dence that proteolytic cleavage is not always necessary for acti-
vation (Stennicke et al., 1999), and endogenous protein inhibitors
exist that control caspase activity through a variety of mecha-
nisms including by binding to the processed forms of the
enzymes (Deveraux et al., 1999; Riedl and Shi, 2004). Adding
to the complexity, some models of apoptosis are dependent
on the release of lysosomal proteases known as cathepsins
that may act through caspase-dependent or independent mech-
anisms (Foghsgaard et al., 2001; Guicciardi et al., 2000, 2001;
Salvesen, 2001; Turk et al., 2002; Vancompernolle et al., 1998;
Yeung et al., 2006). Because of these complications, small mole-
cule inhibitors and substrates targeted against apoptosis-linked
proteases have emerged as attractive alternatives to ascertain
function. Although current commercially available reagents lack
specificity (Kato et al., 2005a), great progress has been made in
this area by the recent development of highly selective activity-
based probes (ABPs) for caspases-3, -7, and -8 (Berger et al.,
2006). These probes have, for instance, allowed for the identifi-
cation of a novel pathway for caspase-7 activation (Denault
et al., 2006).
Here, we describe the development of a cell-permeable ABP
originally designed for the monitoring of caspase activity. We
utilized a previously developed acyloxymethyl ketone warhead
targeted by the general caspase recognition sequence Glu-Val-
Asp (Berger et al., 2006; Kato et al., 2005a, 2005b). The cell
permeability of our probe was engendered through the use
of a two-step labeling procedure in which a bioorthogonal
coupling reaction was used to attach a biotin handle to the
APB after cell lysis (Figure 1A). Unexpectedly, we find that
the conditions of our labeling protocol allow for either the
detection of the effector caspases or the selective monitoring
of the cysteine protease cathepsin B (CatB). CatB belongs to
an 11 member family of cysteine proteases that are typically
localized to lysosomal compartments where it primarily contrib-
utes to protein turnover. Dysregulation of the cathepsins is
linked to a variety of diseases including cancer (Jedeszko
and Sloane, 2004; Mohamed and Sloane, 2006), osteoporosis2, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 1001
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Figure 1. Activity-Based Probe Profiling and Labeling of Recombinant Caspase
(A) Outline of activity-based probe profiling. Apoptotic cells are treated with probe 1, where it will covalently modify proteins based on their endogenous activities.
After cell lysis, the azide handle of 1 will be biotinylated in a secondary labeling step, namely, the Staudinger ligation. Biotinylated proteins can then be analyzed
via western blotting and mass spectrometry.
(B) Two-step labeling of recombinant caspases in a complex proteome. Recombinant caspases were added to MCF7 lysates and subsequently labeled with
probe 1. Staudinger ligations were performed with 2, followed by analysis by streptavidin blotting. Expected molecular weights: caspase-3 (17 kDa), caspase-6
(19 kDa), caspase-7 (19 kDa), caspase-9 (18 kDa), and procaspase-3 (35 kDa). Bands at 75 and 100 kDa are endogenously biotinylated proteins.(Saftig et al., 1998), and immunological defects resulting from
inefficient major histocompatibility class II antigen presentation
(Shi et al., 1999). In addition to its role in lysosomal protein
degradation, CatB is also secreted from certain cancer cells
where it has been implicated in their detachment and migration
(Gocheva et al., 2006; Roshy et al., 2003; Schraufstatter et al.,
2003).
Cytosolic relocalization of CatB has been shown to be impor-
tant in cell death (Kirkegaard and Jaattela, 2009). Lysosomal
release of CatB has previously been observed upon stimulation
of the extrinsic pathway of apoptosis (Foghsgaard et al., 2001;
Guicciardi et al., 2000, 2001). Moreover, this release is impli-
cated in the cross-activation of caspase-9 by caspase-8,
thereby linking the extrinsic and intrinsic apoptotic pathways
(Guicciardi et al., 2000). In addition, drugs such as bortezomib
and granulysin and exposure to UVA/B light have been shown
to permeabilize lysosome membranes and induce cathepsin-
dependent cell death (Bivik et al., 2006; Droga-Mazovec et al.,
2008; Yeung et al., 2006; Zhang et al., 2009). However, the extent
of proteolytic activity CatB retains after this translocation event in
living cells is less clear or whether CatB release is also a feature
of cell death initiated through the intrinsic apoptotic pathway.
Our labeling data show that CatB is active in the cytosol of intact
cells following stimulation of both the intrinsic and the extrinsic
pathways. In the case of the intrinsic pathway, this change in
CatB activity is dependent on caspase-9. In addition, intrinsic
caspase activation in CatB null cells was both delayed and
suboptimal. CatB has been shown in the examples above to
induce the release of cytochrome c from mitochondria, the first
step in caspase-9 activation, and our own biochemical studies
indicate that CatB can cleave caspase substrate sequences at
cytosolic pH. The development of our cell-permeable and selec-
tive probe allowed us to uncover a positive regulatory role for
CatB in a feed-forward loop during the intrinsically activated
cell death program through one of the two mechanisms outlined
above.1002 Chemistry & Biology 16, 1001–1012, September 25, 2009 ª200RESULTS
Labeling of Recombinant Caspases
We synthesized azide-containing probe 1 (see Scheme S1 avail-
able online; Figure 1A) and set out to characterize its activity
against the family of caspase proteases. We first examined its
ability to label recombinant caspases in a complex cell lysate.
Recombinant active caspase-3, -6, -7, and -9, as well as inactive
zymogen of caspase-3 (p3) were added separately in equal
amounts to cell lysate derived from MCF7 cells. MCF7 cells
lack caspase-3 and have very low levels of endogenous caspase
activity, providing a suitable background (Yang et al., 2001).
Probe 1 (300 nM) was then added and lysate was labeled for
30 min. Excess probe was then removed and phosphine-biotin
2 (250 mM; Figure 1A) was added to biotinylate reactive alkyl
azides via the Staudinger ligation (Lin et al., 2005; Saxon and
Bertozzi, 2000). After 2 hr at 37C the secondary labeling reac-
tion was terminated by precipitation and biotinylation was
accessed by streptavidin blotting (Figure 1B). All recombinant
active caspases were labeled, whereas, as expected, inactive
full-length capase-3 remained untouched by the probe
(Figure 1B).
Labeling in Living Cells
Next we analyzed the ability of 1 to label caspases in intact cells
undergoing apoptosis. Toward this end, NIH 3T3 cells were
treated with staurosporine (1 mM) or DMSO vehicle for 3 hr and
were then treated with probe 1 (300 nM) for 30 min. The cells
were harvested, washed thoroughly, lysed, and reacted with
phosphine-biotin 2 as above. Streptavidin blotting revealed the
presence of a single biotinylated protein band at a molecular
weight of 30 kDa in apoptotic cells but not healthy cells
(Figure 2A). This selectivity is diminished when the proteome is
labeled with 1 after lysis (Figure 2A). Note that when higher
concentrations of 1 (5–50 mM) were used, we observed this
same, labeled protein band in nonapoptotic cells (Figure S1A).9 Elsevier Ltd All rights reserved
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Figure 2. Probe Labeling of Intact Cells
(A) Labeling of intact cells and cell lysates by probe 1. NIH 3T3 cells were treated with staurosporine (1 mM) or DMSO vehicle. In the case of cellular labeling, probe
1 (300 nM) was added, followed by lysis and biotin modification with 2 via Staudinger ligation. For lysate modification, cells were lysed and then treated with 1
(300 nM) followed by reaction with 2.
(B) Labeling of intact cells by the alkyne-bearing probe 3. NIH 3T3 cells were again treatedwith staurosporine (1 mM) or DMSO vehicle. Probe 3 (300 nM) what then
added to the cells, followed by lysis and copper catalyzed cycloaddition chemistry with azide biotin 4. In both cases probe labeling was analyzed by streptavidin
blotting. Caspase activation was monitored by western blotting for cleavage from inactive proenzymes to active enzymes. Endogenous caspase-9 differs in
weight from recombinant caspase-9 due to extra domains involved in its activation.Thus, there is a concentration threshold (1 mM) belowwhich the
visualization of this protein appears to be apoptosis dependent.
Surprisingly, the molecular weight of this biotinylated protein
was inconsistent with either active caspase-9 (35 kDa) or activeChemistry & Biology 16, 1001–10caspases-3, -6, and -7 (21, 19, and 17 kDa). Affinity enrichment
of biotinylated proteins followed by anticaspase blotting also
suggested our probe did not label cellular caspases
(Figure S2). To ensure that the apoptotic program had in fact12, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 1003
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using antibodies against caspase-3, -7, -8, and -9 (Figure 2A).
Consistent with activation of the intrinsic pathway, caspases-3,
-7, and -9, but not caspase-8, all showed proteolytic processing
to their active forms.
Wewere concerned that the apparent lack of caspase labeling
may stem from a low efficiency of the Staudinger ligation step.
To explore this, we took advantage of an alternative bioorthogo-
nal coupling reaction, the Huisgen 1,3-dipolar cycloaddition
between an organic azide and an alkyne, which has been re-
ported to be quantitative when compared to direct labeling
methods (Speers et al., 2003). This reaction can be catalyzed
by Cu(I) salts (Wang et al., 2003) and has seen great utility for
the secondary labeling of several ABPs (Sieber et al., 2006;
Speers et al., 2003; Speers and Cravatt, 2004). Probe 3 (Ak-
EVD-AMK; Figure 2B) was synthesized in a similar fashion as
1, bearing an alkyne reactive handle in place of the azide. The
alkyne of 3 presents an alternative reactivity profile, when
compared to the azide, and will for example be resistant to
conditions that may reduce the azide of 1 (Agard et al., 2006).
NIH 3T3 cells were treated with staurosporine (1 mM) followed
by probe 3 (300 nM) for 30 min. Following cell lysis, alkyne-
bearing proteins were reacted with azido-biotin 4 under copper
catalyzed cycloaddition conditions. Western blot analysis again
showed biotin labeling of only one band at 30 kDa in apoptotic
cells, despite that fact that caspases had been activated by the
staurosporine treatment (Figure 2B). We also performed a similar
labeling experiment with probe 3 in which an azido-rhodamine
derivative was used in the secondary labeling step (Charron
et al., 2009). In this case the labeled proteins can be visualized
by direct fluorescence imaging as opposed to western blotting.
This allows us to explore if the problem stems from an inability
of streptavidin-HRP to recognize the biotin moiety in the context
of the labeled caspases. Once again, however, we observed
labeling of a single 30 kDa protein band in apoptotic cells but
not in healthy cells (Figure S3).
150
100
75
kDa
Streptavidin-HRP
50
37
25
20
Staurosporine
Az-EVD-AMK
+ + -
- ++
Input Avidin IP
150
100
75
kDa
50
37
25
20
Input Avidin IP
+ + -
- ++
+ + -
- ++
α-Cathepsin B
MWWSLILLSCLLALTSAHDKPSFHPLSDDLINYINKQNTTWQAGRNF
YNVDISYLKKLCGTVLGGPKLPGRVAFGEDIDLPETFDAREQWSNC
PTIGQIRDQGSCGSCWAFGAVEAISDRTCIHTNGRVNVEVSAEDLLT
CCGIQCGDGCNGGYPSGAWSFWTKKGLVSGGVYNSHVGCLPYTIP
PCEHHVNGSRPPCTGEGDTPRCNKSCEAGYSPSYKEDKHFGYTSY
SVSNSVKEIMAEIYKNGPVEGAFTVFSDFLTYKSGVYKHEAGDMMG
GHAIRILGWGVENGVPYWLAANSWNLDWGDNGFFKILRGENHCGI
ESEIVAGIPRTDQYWGR
A
B
+ + -
- ++
Figure 3. Identification of the Target of Probe 1 by Streptavi-
din Affinity Purification
NIH 3T3 cells were treatedwith staurosporine (1 mM) followed by probe
1 (300 nM). The Staudinger ligation was performed and labeled
proteins were enriched by incubation with streptavidin-agarose
beads.
(A) CatB amino acid sequence with the propeptide highlighted in blue
and peptides identified by mass spectrometry in red.
(B) Streptavidin and CatB western blot analysis of enriched pro-
teomes.
Conceivably, steric hindrance within the enzyme active
site could impede the secondary labeling reaction. To
examine this possibility, NIH 3T3 cells were treated with
staurosporine (1 mM) and 3 (300 nM) as above. The cells
were collected, washed, lysed, and precipitated to dena-
ture the proteome. The precipitated proteins were then re-
suspended in a 4% SDS buffer and subjected to the
cycloaddition conditions with azido biotin 4. Under these
labeling conditions we observed two bands at 17 kDa
(in addition to the 30 kDa band) corresponding to the
expected molecular weight of the effector caspases-3
and -7 (Figure 2B and Figure S3). To further confirm the identity
of these bands, we devised a competition experiment involving 1
and the commercially available biotin-VAD-fluoromethyl ketone,
which can be used to label effector caspases following cell
lysis. Pretreatment of apoptotic cells with increasing concentra-
tions of 3 led to a dose-dependent block of effector caspase
labeling by biotin-VAD-fluoromethyl ketone added after lysis
(Figure S1B).
Identification of Probe-Labeled Protein
To determine the identity of the protein labeled by our probes
under nondenaturing conditions, lysates from apoptotic NIH
3T3 cells prior treated with or without 1 were reacted with biotin
probe 2 and incubated with streptavidin beads. Proteins cap-
tured on the beads were denatured and subjected to on-bead
digestion by trypsin. Tryptic peptides eluted from streptavidin
beads were collected and identified by tandem mass spectrom-
etry (LC-MSMS). Assessment of eluted peptides revealed the
cysteine protease CatB as the only protein present in probe-
treated cells when compared to the control sample (Figure 3A).
To confirm this result, streptavidin affinity enrichment was per-
formed and analyzed by western blotting with a CatB-specific
antibody (Figure 3B). Consistent with the mass spectrometric
analysis, CatB was greatly enriched from apoptotic cells treated
with probe 1 compared to healthy cells. As further validation, we
found that probe 1 could label recombinant CatB in the presence
of cell lysates and that no labeling was observed when CatB null
(catB/) cells (from the corresponding knockout mouse) were
treated with our probes (Figure S4).
Labeling of CatB was observed only in staurosporine-treated
cells even though total levels of CatB in apoptotic and nonapop-
totic cells remain constant (Figure 4A). This suggests that there is
an alteration in the enzymatic activity following activation of the
intrinsic apoptotic pathway. To see whether a similar phenom-
enon occurs upon activation of the extrinsic apoptotic cascade,
we treated NIH 3T3 cells with cycloheximide (10 mg/mL) and
1004 Chemistry & Biology 16, 1001–1012, September 25, 2009 ª2009 Elsevier Ltd All rights reserved
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Figure 4. Streptavidin and CatB Western Blot Analysis of Probe 3 Labeling
(A) NIH 3T3 cells were treated with staurosporine (1 mM) followed by 3 (300 nM).
(B) NIH 3T3 cells were treated with TNF-a (10 ng/mL) and cycloheximide (10 mg/mL) followed by 3 (300 nM).
(C) A variety of cell lines were treated with staurosporine (1 mM) followed by 3. In all cases cycloaddition reactions were performed with 4, followed by streptavidin
and western blotting.tumor necrosis factor-a (TNF-a; 10 ng/mL) for 5 hr before addi-
tion of 3 to the media for 30 min. The cells were collected, sub-
jected to cycloaddition conditions, and analyzed by western
blotting (Figure 4B). We observed labeling of a single band
consistent with CatB only in cells treated with TNF-a. Western
blotting against caspase-8 indicated that the extrinsic pathway
had indeed been initiated under these conditions (Figure 4B).
Although CatB has previously been implicated in TNF-a-
induced apoptosis (Foghsgaard et al., 2001; Guicciardi et al.,
2000, 2001), our data are the first evidence for a change in
cellular CatB activity following initiation of the intrinsic pathway
in intact cells. To ascertain whether this is a general phenomenon
or one specific to NIH 3T3 cells, a panel of cell lines were treated
with staurosporine (1 mM) followed by ABP 3 (300 nM) and biotin
labeling with 4. All cell types tested, with the exception of Jurkat
cells, showed robust labeling of a protein, consistent with CatB
upon treatment with staurosporine (Figure 4C). Thus, an alter-
ation in cellular CatB activity, as reported by our APBs, appears
to be a common feature of staurosporine-induced apoptosis.
Next we asked whether other activators of the intrinsic pathway
would also lead to an alteration in CatB activity. Accordingly, we
treated NIH 3T3 cells with the topoisomerase II inhibitor, etopo-
side, followed by ABP 3 (300 nM) and biotin labeling with 4.
Consistent with the staurosporine studies, we observed labelingChemistry & Biology 16, 1001–10of a single 30 kDa protein band in apoptotic cells and no
labeling in healthy cells (Figure S5). Thus, we have identified
conditions (i.e., treatment with low concentration of probe and
secondary labeling under native folding conditions) in which
probes 1 or 3 allow selective labeling of CatB upon activation
of either the intrinsic or extrinsic apoptotic pathways.
Labeling of CatB Is Dependent on the Apoptotic
Cascade
To determine if our activity-based probe is labeling CatB in an
apoptosis-dependent manner and not as an indirect result of
staurosporine treatment, we took advantage of immortalized
mouse embryonic fibroblast (MEF) cells derived from caspase-
9 null mice (Masud et al., 2007). Caspase-9 null MEF cells and
wild-type MEF cells as a positive control (from knockout mice
and wild-type littermates, respectively) were treated with staur-
osporine (1 mM) for 3 hr followed by treatment with probe 3
(300 nM) for 30 min. The cells were harvested, washed thor-
oughly, lysed, and labeled with azido-biotin 4 as above. As ex-
pected, western blot analysis showed labeling of a band of
30 kDa inwild-typeMEF cells corresponding to CatB (Figure 5).
In contrast, little or no labeling of CatB was observed in the cas-
pase-9 null MEF cells, despite equal amounts of protein as deter-
mined by anti-CatB blotting.12, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 1005
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Figure 5. Probe Labeling of CatB in Caspase-9 Null Cells
Wild-type or caspase-9 null cells were treated with staurosporine (1 mM) to activate caspases. The cells were then treated with 3 (300 nM), followed by lysis,
cycloaddition, and analysis by streptavidin and western blotting.CatB Is Active at Cytosolic pH and Can Cleave Caspase
Substrates
Several studies indicate that CatB, which normally resides in
lysosomes, is released into the cytosol upon activation of the
extrinsic apoptotic pathway (Foghsgaard et al., 2001; Guicciardi
et al., 2000, 2001; Vancompernolle et al., 1998). We reasoned
that our probe may be reporting on this relocalization of CatB
and would therefore provide the first direct measurement of
CatB activity in the cytosol during apoptosis. For this to be the
case several criteria must be met: CatB must be active at cyto-
solic pH, our probes must be able to label CatB in the cytosol
but not in the lysosome, and CatB must be released into the
cytosol following activation of both the intrinsic and the extrinsic
apoptotic pathways (since we see CatB labeling in both cases).
To address the first of these criteria, we measured the activity
of purified CatB from human liver at pH 5 and 7 using both a
cathepsin-directed peptide substrate (Z-Phe-Arg-AMC) as well
as a panel of caspase substrates (Figure 6A). Although Z-Phe-
Arg-AMC was the preferred substrate in this in vitro assay,
CatB was found to cleave all of the caspase substrates tested.
Moreover, this activity profile did not change appreciably
between pH 4 and 7. These results are in good agreement with
previous biochemical studies that indicate that CatB retains
significant catalytic activity at pH 7 and can cleave, and be in-
hibited by, caspase-directed substrates and inhibitors, respec-
tively (Foghsgaard et al., 2001; Khouri et al., 1991; Koga et al.,
1991). Collectively, this data suggests that cytosolic CatB is
able to cleave proteins with more prototypical cathepsin cleav-
age sites, as well as substrates containing caspase cleavage
sites.
CatB Is Released into the Cytosol during Apoptosis
where It Is Labeled by the Probe
Next we asked whether there is measurable CatB activity in the
cytosol of apoptotic cells. NIH 3T3 cells were treated with staur-
osporine (1 mM) for 3 hr and a cytosolic fraction was then1006 Chemistry & Biology 16, 1001–1012, September 25, 2009 ª20prepared using a digitonin extraction protocol (Foghsgaard
et al., 2001). The remaining cell pellet was resuspended in
NP-40 lysis buffer and centrifuged to provide a sample, termed
NP40 soluble, enriched in organelles. These fractions were
then assayed for cathepsin activity using the Z-Phe-Arg-AMC
fluorescent substrate described above. An increase in cytosolic
cathepsin activity was observed in staurosporine-treated cells
compared to nonapoptotic cells (Figure 6B). Furthermore, this
activity could be inhibited by the cathepsin inhibitor E64 (Barrett
et al., 1982), ruling out caspase activity in our assay. Similar
results were obtained using cytosolic fractions derived from
NIH 3T3 cells treated with TNF-a (Figure S6).
With evidence of CatB release into the cytoplasm during
apoptosis, we designed a competition assay to determine if
our probe was indeed reporting on this relocalization. The
cathepsin inhibitor E64 is not freely diffusible across cellular
membranes and therefore unable to covalently modify cytosoli-
cally localized proteases in intact cells (Huang et al., 1992).
However, it can access lysosomes through endocytosis and
can therefore inhibit lysosomally localized cathepsins (Hang
et al., 2006). This being the case, we reasoned that treatment
of cells with E64 prior to addition of our probe should result in
covalent inhibition of the entire lysosomal pool of CatB, resulting
in a complete loss of labeling by 3. Indeed, when NIH 3T3 cells
were treated with E64 for 3 hr prior to either a selective concen-
tration of 3 (300 nM) in apoptotic cells or a nonselective concen-
tration of 3 (5 mM) in healthy cells, all CatB labeling was lost
(Figure 6C). We interpret this result to mean that prior to the
induction of apoptosis, CatB is localized to the lysosomes and
covalently inhibited by E64.
This allowed us to perform a similar experiment by co-treating
cells with E64 and probe 3. We presumed that treatment of
healthy cells with a high concentration of probe 3 (5 mM) leads
to labeling of lysosomal CatB. Therefore co-treatment with an
excess E64 (50 mM) should result in loss of probe 3 labeling,
which was indeed the case (Figure 6C). In contrast, we09 Elsevier Ltd All rights reserved
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Figure 6. Probes 1 and 3 Read Out the
Release of CatB into the Cytosol during
Apoptosis
(A) CatB cleavage of caspase-like substrates at
lysosomal and cytosolic pH. Purified CatB was
incubated with several fluorogenic caspase pep-
tide substrates for 30 min at 37C and fluores-
cence of released amino-methylcoumarin (AMC;
excitation at 380 nM; emission at 460 nM) was
measured. Fluorescence was normalized to
a canonical CatB substrate, Z-FR-AMC.
(B) Measurement of CatB activity in the cytosol
during the intrinsic pathway of apoptosis. NIH
3T3 cells were treated with staurosporine (1 mM)
or DMSO vehicle for 3 hr. The cytosol was then
extracted with digitonin (labeled cytosol) and the
remaining pellet was resuspended in NP-40 lysis
buffer (labeled NP40 soluble). The fluorescent
substrate Z-FR-AMCwas then added and fluores-
cence was measured. The cathepsin inhibitor E64
inhibited the fluorescence signals.
(C) Competition of probe 3 labeling by the CatB
inhibitor E64. NIH 3T3 cells were either pretreated
with E64 (50 mM) for 1 hr prior to activation with
staurosporine (1 mM) or DMSO vehicle for 3 hr.
Staurosporine-treated cells were then treated
with 3 alone (300 nM or 5 mM) or cotreated with 3
(300 nM or 5 mM) and E64 (50 mM) for 30 min prior
to lysis and cycloaddition. Nonapoptotic cells
were treated with 3 alone (5 mM) or cotreated
with 3 (5 mM) and E64 (50 mM) for 30 min prior to
lysis and cycloaddition. All samples were then
analyzed by streptavidin blotting.
(D) Comparison of staurosporine-induced cas-
pase activity in CatB null and wild-type fibroblasts.
CatB null or wild-type fibroblasts were treated with
staurosporine (1 mM) and caspase activity was
measured at different treatment times using a cas-
pase-dependent luminescence kit. Experiments in
(A), (B), and (D) were performed in triplicate and
errors are standard deviation (*p < 0.05, students
t test).presumed that treatment of apoptotic cells with a low concentra-
tion of probe 3 (300 nM) leads to labeling of mostly cytosolic
CatB. This being the case, co-treatment with excess E64 should
have little or no effect, which was our observation.
To ensure that E64 uptake is not simply impaired in apoptotic
cells, we performed one additional experiment. We supposed
that in apoptotic cells CatB resides in both the lysosome and
cytosol and treatment with probe 3 at a high concentration
(5 mM) will label both of these pools. If apoptotic cells can take
up E64, co-treatment with excess E64 (50 mM) should result in
loss of lysosomal labeling by probe 3. The end result of this
co-treatment would be labeling of solely the cytosolically local-
ized CatB at a level similar to probe 3 at 300 nM, which is again
what we observe (Figure 6C). Thus, the labeled CatB observed in
apoptotic cells co-treated with probe 3 and E64 represents the
cytosolic population of the protein.Chemistry & Biology 16, 1001–101CatB Is a Positive Regulator of the Intrinsic Apoptotic
Cascade
CatB has been previously shown to be involved in crosstalk
between the extrinsic and intrinsic apoptotic pathways (Guic-
ciardi et al., 2000), where activation of caspase-8 by treatment
with TNF-a resulted in the release of CatB from lysosomes.
Furthermore, use of a cell-free system indicated that active cas-
pase-8 could release CatB from purified lysosomes and that
CatB, in turn, resulted in the activation of the intrinsic pathway
through the release of cytochrome c from the mitochondria
(Guicciardi et al., 2000). Consistent with this model, cells isolated
from CatB null mice also showed diminished cytochrome c
release, caspase activation, and apoptosis when treated with
TNF-a (Guicciardi et al., 2000, 2001).
Because the intrinsic cell death pathway is typically initiated by
the release of cytochrome c, we rationalized that CatB may be2, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 1007
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apoptosis and set out to test that hypothesis. CatB null
(catB/) and wild-type fibroblasts (from knockout mice and
wild-type littermates, respectively) were treated with staurospor-
ine (1 mM) and caspase-3 and -9 activities were measured at
different times using an ex vivo caspase-dependent lumines-
cence assay (Figure 6D). Both caspase-3 and -9 activities were
diminished and delayed in CatB null cells when compared to
wild-type controls. This suggests that CatB plays a role as a posi-
tive regulator not only in caspase-8-initiated cell death but also in
the timely and efficient activation of the intrinsic apoptotic
pathway.
DISCUSSION
We have described the serendipitous discovery of cell perme-
able activity-based probes that allow labeling of the lysosomal
protease CatB in apoptotic cells. These probes were originally
designed to visualize activated caspases via a two-step labeling
scheme employing a bioorthogonal coupling reaction, either the
Staudinger ligation or copper-catalyzed Huisgen cycloaddition.
However, several lines of evidence including mass spectrometry
and coimmunoprecipitation analyses (Figure 3) indicate that this
labeling strategy instead results in the selective visualization of
cytosolic CatB activity. Indeed, selective CatB labeling was
observed in several different cell lines, regardless of the stimulus
used to induce apoptosis (Figure 4). Activity probes that allow
labeling of cathepsins (including CatB) in intact cells are known
(Blum et al., 2005, 2007); however, selective visualization of
CatB in apoptotic cells has not been reported previously.
That our probes should label CatB in cells is not entirely unex-
pected considering that previous studies have shown that cas-
pase-targeted substrates and inhibitors can cross-react with
CatB in vitro (Foghsgaard et al., 2001; Gray et al., 2001; Guic-
ciardi et al., 2000, 2001; Rozman-Pungercar et al., 2003; Van-
compernolle et al., 1998). More surprising was the lack of detect-
able caspase labeling in our initial cell-based experiments,
particularly since probe 1 does label recombinant caspases
added to cell lysates (Figure 1B). A likely explanation for this
comes from our finding that endogenous effector caspases
can be visualized when the secondary labeling reaction is per-
formed under conditions expected to denature the cellular pro-
teome (Figure 2B). This suggests that steric hindrance of the
secondary labeling reaction in the caspase active site may be
partly responsible for the lack of observable caspase labeling
in the absence of denaturants. We propose that this steric
problem, perhaps in combination with low levels of the activated
caspases to begin with, places caspases below the detection
threshold using our standard two-step labeling conditions.
Presumably, CatB is above this threshold because it is more
abundant and/or because the secondary labeling reaction is
more efficient in this context. The net result of this is a labeling
protocol for selectively visualizing CatB activity in apoptotic
cells.
An ever-growing body of evidence has identified the CatB
protease as an important participant in TNF-a-induced apo-
ptosis (Foghsgaard et al., 2001; Guicciardi et al., 2000, 2001),
and increase in CatB expression and activity initiates apoptosis
in cells treatedwith an attenuated strain ofMycobacterium bovis,1008 Chemistry & Biology 16, 1001–1012, September 25, 2009 ª20bacillus Calmette-Gue´rin (Sandes et al., 2007). Some small
molecules and UVA/B light have also been shown to cause lyso-
somal permeabilization resulting in cathepsin-dependent cell
death (Bivik et al., 2006; Droga-Mazovec et al., 2008; Yeung
et al., 2006; Zhang et al., 2009). Additionally, staurosporine-
induced apoptosis has been shown to be diminished in inclu-
sion-cell disease fibroblasts, which have lowered levels of
cathepsins B, D, and L (Terman et al., 2002). We have bolstered
those results by providing the first direct measurement of CatB
activity in the cytosol of intact apoptotic cells. We also provide
direct evidence that CatB is released from lysosomes during
the cell death pathway initiated by the intrinsic pathway in addi-
tion to the extrinsic apoptotic cascade (Figure 4). Interestingly,
we did not observe CatB labeling in a MEF cell line lacking
caspase-9, suggesting that release of CatB from lysosomes is
downstream of the initiator caspase in the intrinsic pathway.
Previous studies have indicated that caspase-8 is required for
lysosomal release of CatB upon stimulation of the extrinsic path-
way (Foghsgaard et al., 2001; Guicciardi et al., 2001). Indeed, it
has been shown that recombinant caspase-8 can induce CatB
release from purified lysosomes in a cell-free system (Guicciardi
et al., 2000). Thus, it is possible that caspase-9 plays a similar
role to caspase-8 in this lysosomal release phenomenon. Addi-
tional studies will be needed to further test this idea.
Upon induction of the intrinsic apoptotic pathway, we rea-
soned that CatB could be taking a role as a positive regulator
of cell death by participating in a feed-forward activation loop,
in addition to findings in previous reports that it can induce
apoptosis. Feed-forward and -back loops are a hallmark of
many biological signaling cascades whereby cells can tune their
sensitivity to intra- and extracellular stimuli. The proteolytic cas-
cade of caspase activation is a well-studied example of this.
Caspase-9 is both an upstream activator and substrate of cas-
pase-3, and the presence of caspase-3 has been shown to be
essential for efficient activation of caspase-9 (Slee et al., 1999;
Zou et al., 2003). We propose that CatB is a previously unidenti-
fied positive regulator of this important feedback machinery
(Figure 7). One possible mechanism is CatB acting to reinforce
the release of additional cytochrome c, thereby activating addi-
tional caspase-9. We have also showed that CatB is able to
cleave peptides containing canonical caspase recognition sites
(Figure 6A). Therefore, cytosolic CatB could also be directly acti-
vating caspases through proteolytic cleavage. Consistent with
both hypotheses, CatB null cells treated with staurosporine
show delayed and reduced activation of both caspase-9 and
caspase-3 when compared to wild-type controls (Figure 6D).
Further studies will be needed to test these ideas and to better
understand the mechanism of the lysosomal release process
generally. The ability to detect cytosolic CatB in intact cells using
our probes should be helpful in this regard.
SIGNIFICANCE
The development of a cell-permeable cathepsin B (CatB)
probe facilitated the further investigation into the role this
important protease plays in cell death. Previous studies
have relied upon indirect measurements and in vitro experi-
mentation to visualize the release of CatB from lysosomes.
The data presented here are the first direct visualization of09 Elsevier Ltd All rights reserved
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We have used this chemical advance to explore a role for
CatB in the intrinsic apoptotic pathway. Biochemical char-
acterization of caspase-9 and CatB null cell lines places
the release of CatB into the cytosol downstream of cas-
pase-9, where it plays a role in the timely activation of the
caspase proteolytic cascade. We hypothesize that CatB is
acting through two nonmutually exclusive pathways. Mirror-
ing its role in the crosstalk between the extrinsic and
intrinsic apoptotic programs, CatB could release cyto-
chrome c from the mitochondria resulting in further activa-
tion of caspase-9. Furthermore we have shown that CatB
can cleave peptide substrates bearing canonical caspase
recognition sequences, implicating CatB in the direct
cleavage of caspase substrates. In summary, we propose
that in addition to its previously understood role in apoptotic
pathway crosstalk, CatB is an important member of the
highly controlled feed-forward loop that ensures full cas-
pase activation during intrinsically stimulated cell death.
EXPERIMENTAL PROCEDURES
All chemicals were obtained from commercial suppliers and were used as
received unless otherwise noted. Staurosporine, E64, and Z-VAD-FMK were
obtained from EMD Biosciences. Recombinant caspases and CatB purified
from human liver were obtained fromBiomol. Phosphine-biotin (2) was synthe-
sized as previously described (Saxon and Bertozzi, 2000). PEO3-biotin was
purchased from Pierce. Streptavidin-agarose and Softlink soft release avidin
Mitochondria
CatB Caspase-9
Apoptosis
Cytochrome C
a
b
Figure 7. CatB as a Positive Regulator of the Intrinsic Apoptotic
Cascade
Two nonmutually exclusive mechanisms are proposed. Active caspase-9 first
results in release of CatB from the lysosome. In pathway a, cytosolic CatB
results in the release of more cytochrome c from the mitochondria, reinforcing
the activation of additional caspase-9. In addition, CatB can participate
directly in apoptosis (pathway b) by proteolyzing proteins at canonical
caspase cleavage sites.Chemistry & Biology 16, 1001–10resin were purchased from Sigma and Promega, respectively. Caspase
substrates were purchased from EMD Biosciences.
Probe Synthesis
Probes 1 and 3 were synthesized using commercially available amino acids
and standard Fmoc solid phase peptide synthesis using DIC/HOBt coupling
chemistry and modifications outlined in Kato et al. (2005a) Probes were
then purified by RP-HPLC and identities were confirmed by ESI-MS; calcu-
lated for 1 C50H71N9O14 (M+H) 1022.51, found 1022.99; calculated for 3
C51H70N6O14 (M+H) 992.50, found 992.46.
Synthesis of Azido-biotin 4
Known azidovaleric acid (Seo et al., 2003) was activated to the corresponding
pentafluorophenyl ester as follows. Azidovaleric acid (500 mg, 3.50 mmol) was
dissolved in CH2Cl2 (5 mL) and pyridine (310 mL, 3.84 mmol) followed by pen-
tafluorophenyl trifluoroacetate (690 mL, 4.00 mmol). The reaction was stirred
for 45 min, washed with 1 N HCl, 10% NaHCO3, and H2O. The organic layer
was dried over Na2SO4, filtered, and concentrated. This solid pink material
(43 mg, 0.14 mmol) was added to a solution of PEO3-biotin (50 mg,
0.12 mmol) in DMF (2 mL) and the reaction was stirred for 16 hr. At this time
the mixture was concentrated and the product purified by silica gel chroma-
tography (7:2:1 ethyl acetate:MeOH:H2O) to yield 53 mg (81%) as an off white
powder. 1H NMR (400MHz, D2O) d 4.57 (dd, 1 H, J = 5.0, 7.8 Hz), 4.38 (dd, 1 H,
J = 4.5, 7.8 Hz), 3.59 (app t, 6 H, J = 5.3 Hz), 3.35 (app t, 6 H, J = 5.2), 3.32–3.27
(m, 4 H), 2.95 (dd, 1 H, J = 5.0, 13.3 Hz), 2.74 (app d, 1H, J = 13.0 Hz), 2.27–2.22
(m, 4 H), 1.74–1.52 (m, 8 H), 1.41–1.34 (m, 4 H); 13C NMR (125 MHz, D2O)
d 177.28, 176.98, 165.75, 70.11, 69.87, 69.32, 62.52, 60.69, 55.80, 51.81,
40.14, 39.35, 35.91, 35.63, 28.35, 28.15, 27.89, 25.58, 23.07; ESI-MS calcu-
lated for C23H41N7O6S (M+H) 544.28, found 544.99.
Labeling of Recombinant Caspases
MCF7 cells, grown to confluency, were collected from a 10 cm dish by gentle
scraping and pelleted by centrifugation at 2000 3 g. After the cell pellet was
washed with PBS (1 mL) two times, the cells were lysed in 200 ml of ice-cold
NP lysis buffer (0.5% NP-40, 50 mM Tris, and 5 mM MgCl2 [pH 7.4]) for
20 min and centrifuged at 4C for 10 min at 10,000 3 g. The supernatant
(post-nuclear lysate) was collected and the protein concentration was deter-
mined by Bradford assay (Bio-Rad). Probe labeling of recombinant caspases
was accomplished by incubation of MCF7 cell lysate (50 mg) with recombinant
caspase (10 mL, 1000 U) and 1 mM probe 1 (1 mM in DMSO stock) in a total
volume of 100 ml for 90 min at room temperature. The lysates were then
concentrated using Vivaspin (Sartorius) 500 columns (10,000 MWCO PES)
and washed with lysis buffer (500 mL). The resulting protein solutions were
diluted with NP lysis buffer to a volume of 100 ml and subjected to the
Staudinger ligation.
Live Cell Probe Treatment with Intrinsic Pathway Activation
NIH 3T3, wild-type MEFs, caspase-9 null MEFs, CatB null MEFs, CHO, Jurkat,
HEK293, or HeLa cells at80%–90% confluency in a 10 cm dish were treated
with serum-free media (10 mL) for 16 hr. At this time staurosporine (10 mL;
1mM in DMSO)was added to give a final concentration of 1 mM (DMSO vehicle
was added to all control plates). After 3 hr the cells were treated with probes 1
or 3 (0.1 to 50 mM; 10003 in DMSO stock) or DMSO for 30 min. Alternatively,
cells were activated with etoposide (10 mM) and cycloheximide (10 mg/mL) for
12 hr. The cells were then collected by gentle scraping and pelleted by centri-
fugation at 2000 3 g, followed by washing with PBS (1 mL) two times. Cell
pellets from 2.0 3 107 cells were resuspended in 100 ml of ice-cold NP lysis
buffer (0.5%NP-40, 50mMTris, and 5mMMgCl2 [pH 7.4]) with Complete Mini
protease inhibitor cocktail (Roche Biosciences) for 30 min and then centri-
fuged at 4C for 10 min at 10,000 3 g. The supernatant (total cell lysate) was
collected and the protein concentration was determined by Bradford assay.
Extrinsic Pathway Activation
NIH 3T3 cells at 80%–90% confluency in a 10 cm dish were treated with
cycloheximide (10 mg/mL; 10 mg/mL stock in H2O) and TNF-a (10 ng/mL) for
5 hr. At this time, probe 1 (300 nM) was added for 30 min and the cells were
processed as above.12, September 25, 2009 ª2009 Elsevier Ltd All rights reserved 1009
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Staudinger ligation labeling of azide-modified proteins was performed by incu-
bation of post-nuclear lysates (100 mg) with 250 mM of phosphine-biotin (2;
5 mM in DMSO stock) and 5 mM dithiothreitol (50 mM in H2O stock) in a total
reaction volume of 100 ml for 2 hr at 37C. The reactions were terminated by
addition of ice-cold acetone (1 mL), incubated at20C for 20 min, and centri-
fuged at 4C for 10 min at 18,000 3 g to precipitate proteins. The supernatant
was careful decanted and the resulting pellet dried at room temperature for
5 min to remove any excess acetone. The protein pellet was subsequently
resuspended in SDS-protein loading buffer with 2-mercaptoethanol and
boiled for 10 min.
Labeling of Cell Lysates by Cycloaddition
Cells lysates (100 mg) were prepared with modified NP-40 lysis buffer (1%
NP-40, 50 mM triethanolamine, and 150 mM NaCl [pH 7.4]) with Complete
Mini protease inhibitor cocktail (Roche Biosciences) and cycloaddition reac-
tions were performed as follows. Azido-biotin tag (4; 100 mM; 5 mM stock in
DMSO) or azido-rhodamine (100 mM; 5 mM stock in DMSO) was added, fol-
lowed by 1mM TCEP (50mM stock in H2O) and 100 mM triazole ligand (Speers
and Cravatt, 2004) (1.7 mM stock in DMSO/t-butanol 1:4). The samples were
gently vortexed and 1 mM CuSO4 (50 mM stock in H2O) was added. Samples
were vortexed again and allowed to reaction at room temperature for 1 hr. At
this time, the reactions were terminated by addition of ice-cold acetone (1 mL),
incubated at20C for 20min, and centrifuged at 4C for 10min at 18,0003 g
to precipitate proteins. The supernatant was careful decanted and the result-
ing pellet dried at room temperature for 5 min to remove any excess acetone.
The protein pellet was subsequently resuspended in SDS-protein loading
buffer with 2-mercaptoethanol and boiled for 10 min.
Denaturation of Cellular Proteome
NIH cells, grown to confluency and treated with staurosporine and 3 as above,
were collected from a 10 cm dish by gentle scraping and pelleted by centrifu-
gation at 20003 g. After the cell pellet was washed with PBS (1 mL) two times,
the cells were lysed in 200 ml of ice-cold modified NP lysis buffer (1% NP-40,
50 mM triethanolamine, and 150 mMNaCl [pH 7.4]) for 20 min and centrifuged
at 4C for 10 min at 10,000 3 g. The supernatant (post-nuclear lysate) was
collected and the protein concentration was determined by Bradford assay
(Bio-Rad). The 200 mg of total protein were then precipitated by addition of
ice-cold acetone (1 mL) and incubation at 20C for 30 min. After centrifuga-
tion at 10,000 3 g for 10 min and careful decanting, the precipitated proteins
were resuspended in SDS buffer (100 ml; 4% SDS, 50mM triethanolamine, and
150 mM NaCl [pH 7.4]) and subjected to the cycloaddition conditions.
Streptavidin Affinity Enrichment of Biotinylated Proteins
Cell lysates (10 mg for mass spectroscopic analysis or 1/10 scale for western
blot analysis) from NIH 3T3 cells treated with 1 as above were reacted with
25 mMof 2 (5 mM in DMSO stock) and 5mMdithiothreitol (50mM in H2O stock)
in a total reaction volume of 10 ml at 37C with rocking. The reactions were
terminated by the addition of ice-cold acetone (40 mL), incubated at 20C
for 20 min, and centrifuged at 4C for 10 min at 10,000 3 g to precipitate
proteins. The supernatant was decanted and the protein pellet was resus-
pended in 10ml of 0.2%SDS and 50mMTris (pH 7.4) with sonication. Proteins
were precipitated again with ice-cold acetone (40 mL) and resuspended in
0.2% SDS and 50 mM Tris (pH 7.4) with sonication to remove any residual
2. Prewashed streptavidin-agarose beads (250 mL; for mass spectroscopic
analysis) or Softlink soft release avidin resin (25 mL; for western blot analysis)
were then added to resuspended protein lysates (1 mg/mL) and allowed to
incubate at 4C for 1 hr with rocking. The beads were centrifuged for 5 min
at 4000 3 g at 4C and washed with 10 ml of 0.2% SDS and 50 mM Tris
(pH 7.4) four times.
Proteomic Analysis of Biotinylated Proteins
Washed streptavidin-agarose beads (250 mL) were washed twice with 1ml of
50 mM triethylammonium bicarbonate (pH 7.4). Attached proteins were then
denatured and reduced with 500 ml of 6 M urea, 10 mM TCEP, and 50 mM trie-
thylammonium bicarbonate (pH 7.4) for 30 min at room temperature with rock-
ing. Iodoacetamide from a stock solution of 1Mwas added to this slurry to give
a final concentration of 20 mM iodoacetamide and was allowed to react for1010 Chemistry & Biology 16, 1001–1012, September 25, 2009 ª2030 min at room temperature with rocking in the dark. The beads were then
washed with 1 ml of 50 mM triethylammonium bicarbonate (pH 7.4) three
times, resuspended in 500 ml of 50 mM triethylammonium bicarbonate
(pH 7.4) with 2 mg of porcine trypsin, and allowed to digest overnight at 37C
with rocking. The beads were centrifuged for 1 min at 40003 g, and the super-
natants were collected and concentrated to a volume of 15 ml by speedvac.
Glacial acetic acid was added to stop digestion and adjust the pH of the solu-
tion to 3.5. The sample was pressure loaded directly onto a 3603 75 mmPico-
Frit column equippedwith a 15 mm tip and a 5 cm bed of BioBasic C18material
(New Objective, Inc.). Subsequently the sample was analyzed on a Finnigan
LTQ (Thermo Fisher Scientific) in positive electrospray mode using a linear
gradient of 0%–100% B over 90 min (A = 0.1 M acetic acid in nanopure water,
B = 70% acetonitrile in 0.1 M acetic acid) and a flow rate of 150 nL/min on
a Smart System HPLC (Pharmacia). The spectra were acquired with the instru-
ment operating in data-dependent mode. A full scan mass spectrum was
followed by 10 MS/MS spectra on the ten most abundant ions. The isolation
window for precursor selection was set to ±1.5 Da, the collision energy to
35%, and the activation Q was set to 0.25. The target value for the full scan
was set to 3e4 and for the MS/MS scan to 1e4. The selected ions were set
on a dynamic exclusion list for 30 s, except predicted tryptic peptides of avidin
were set on a static exclusion list. The MS/MS data was analyzed by using the
open source search engine, X! Tandem (version 2007.01.01), to search the
spectra against the NCBI database using the X! Hunter search algorithm.
Searches were limited to the Mus musculus genome, and the parameters
were set to a fragment mass error of ±0.4 Da. Four tryptic peptides covering
25% of CatB were identified from the fragmentation data. The base-10 log
of the expectation value was 97.4, signifying a high confidence that CatB
was present in the sample. No CatB peptides were identified from a control
sample of apoptotic NIH 3T3 cells that had not been treated with probe 1.
Labeling of CatB In Vitro
Purified CatB (1.5 mg; Biomol) was added to BSA (100 mg) and Jurkat cell lysate
(2 mg/mL; modified NP-40 lysis buffer), 100 ml total volume. DMSO vehicle or
probe 3 (500 mM stock in DMSO; 1 mM final concentration) was then added.
After 1 hr at room temperature, the reaction was terminated by addition of
ice-cold acetone followed by incubation at 20C for 20 min. The resulting
precipitated proteins were centrifuged at 18,000 3 g and the supernatant
was carefully decanted. The protein pellet was washed with ice-cold acetone
twice and then resolubilized in 100 ml of 4% SDS, 50 mM triethanolamine, and
150 mM NaCl (pH 7.4). Cycloadditions were then performed as above.
Western Blotting
Biotin (25 mg) labeled proteins were separated by SDS-PAGE and transferred
to a PVDF membrane and the membrane was blocked with 5% nonfat dried
milk in TBST (50 mM Tris, 150 mM NaCl, and 0.5% Tween 20 [pH 7.6]) over-
night at 4C or 1 hr at room temperature. The membrane was washed with
TBST for 10 min (33 20 mL) and incubated with streptavidin-HRP (GE Health-
care; 1:5000 in TBST) for 1 hr. Themembrane was washed again with TBST for
10 min (3 3 20 mL) and developed using ECL reagents (PerkinElmer) and
Kodak BiomaxMR film. To ascertain levels of endogenous proteins in Figure 2,
equal amounts of protein were run and probedwith anti-caspase antibodies. In
all other figures the above membranes were stripped and blocked as above,
and then probed with anti-caspase antibodies (Cell Signaling Technologies;
1:1000), an anti-CatB antibody (Santa Cruz Biotechnology; 1:300), or an
anti-PARP antibody (BD PharMingen; 1:1000). After washing three times
with TBST, the blots were incubated with HRP-conjugated secondary anti-
bodies (GE Healthcare) for 1 hr in blocking buffer, washed three more times
with TBST, and developed using ECL reagents (PerkinElmer) and Kodak
Biomax MR film.
In Vitro Activity Assay
AMC derivatized peptide substrates (DMSO stocks) were added to an imid-
azole-HCl buffer (pH 4.8 or 7.0) (100 mL) containing 8 mM dithiothreitol and
4 mM EDTA. A solution of CatB (200 ng/mL) in 0.1% Brij 35 solution (5 mL)
was then added. After incubating for 30 min at 37C, the reaction was termi-
nated by addition of 100 mM sodium chloroacetate in 100 mM sodium acetate
buffer (pH 4.3) (150 mL). Fluorescence (excitation at 380 nM; emission at
460 nM) was then measured.09 Elsevier Ltd All rights reserved
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NIH 3T3 cells were either activated for apoptosis with staurosporine or TNF-a
as above or left untreated. The cells were then collected by gentle scraping
and pelleted by centrifugation at 2000 3 g, followed by washing with PBS
(1mL) two times. Cells were treated with 25 mg/mL digitonin, 20mM triethanol-
amine, and 10mMKCl2 for 10min. After centrifugation at 10,0003 g for 10min
the supernatant was collected, which contains the cytosolic fraction. The
pellet was then suspended in modified NP lysis buffer followed by centrifuga-
tion at 10,000 3 g for 10 min. The resulting supernatant contains the NP-40
soluble fraction. Total protein from each fraction (30 mg) was normalized and
then added to an imidazole-HCl buffer (pH 4.8) (100 mL) containing 8 mM
dithiothreitol and 4 mM EDTA and was either treated with the cathepsin inhib-
itor E64 (200 mM) or with DMSO vehicle for 30min. At this time Z-Phe-Arg-AMC
was added to give a final concentration of 200 mMand the reactions were incu-
bated at 37C for 30 min. Fluorescence (excitation at 380 nM; emission at
460 nM) was then measured. All experiments were performed in triplicate.
E64 Competition Experiment
NIH 3T3 cells were either pretreated with E64 (50 mM) for 1 hr prior to activation
with staurosporine (1 mM) or DMSO vehicle for 3 hr. Staurosporine-treated
cells were then treated with 3 alone (300 nM or 5 mM) or cotreated with 3
(300 nM or 5 mM) and E64 (50 mM) for 30min prior to lysis and the cycloaddition
conditions described above. Nonapoptotic cells were treated with 3 alone
(5 mM) or cotreated with 3 (5 mM) and E64 (50 mM) for 30 min prior to lysis
and the cycloaddition conditions.
Measurement of Caspase Activity in CatB Null Cells
CatB null or the corresponding wild-type MEFs (25,000 per well) were plated
in a white plate, clear bottom 96 well assay plate (Corning Incorporated). After
16 hr the cells were washed with PBS and 100 ml media containing staurospor-
ine (1 mM) was added. At the indicated times, 100 ml of Caspase-Glo 3/7 or
Caspase-Glo 9 assay (Promega) was added to the appropriate wells. The
mixtures were incubated for 45 min and luminescence was measured accord-
ing to the manufacturer’s directions using a 96 well luminometer (Molecular
Biosystems).
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scheme, and six figures and can be found with this article online at http://
www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00243-9.
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